The Myasthenia Gravis-Specific Activities of Daily Living Profile

被引:56
作者
Muppidi, Srikanth [1 ]
机构
[1] Univ Texas SW Med Ctr Dallas, Dept Neurol & Neurotherapeut, Dallas, TX 75390 USA
来源
MYASTHENIA GRAVIS AND RELATED DISORDERS I | 2012年 / 1274卷
关键词
myasthenia gravis outcome measures; MG-ADL; MG Composite; MG QOL15; LOW-DOSE TACROLIMUS; MYCOPHENOLATE-MOFETIL; OUTCOME MEASURES; TRIAL;
D O I
10.1111/j.1749-6632.2012.06817.x
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
The myasthenia gravis activities of daily living (MG-ADL) profile is an eight-item patient-reported scale developed to assess MG symptoms and their effects on daily activities. The MG-ADL profile correlated well with the Quantitative MG (QMG) score (r = 0.58, P < 0.001) in 254 consecutive patient visits. Further analysis during clinical trials confirmed the excellent correlation with the QMG test and provided additional evidence that the MG-ADL profile is responsive to clinical improvement. MG-ADL performance was further analyzed during a recent multicenter, prospective scale validation study for two new outcome measures. At the first visit, there was a strong positive correlation between the MG-ADL and the MG Composite (r = 0.85, P < 0.0001) and between the MG-ADL and the MG-Quality of life15 (MG-QOL15) (r = 0.76, P < 0.0001). Test-retest analysis demonstrated a high reliability coefficient. Sensitivity/specificity analysis revealed that a 2-point improvement has the best trade-off attributes to predict clinical improvement. The MG-ADL profile also performed well on Rasch analysis. The MG-ADL scoring system is useful as a secondary outcome measure and in routine clinical management.
引用
收藏
页码:114 / 119
页数:6
相关论文
共 15 条
[1]   Reliability testing of the quantitative myasthenia gravis score [J].
Barohn, RJ ;
McIntire, D ;
Herbelin, L ;
Wolfe, GI ;
Nations, S ;
Bryan, WW .
MYASTHENIA GRAVIS AND RELATED DISEASES: DISORDERS OF THE NEUROMUSCULAR JUNCTION, 1998, 841 :769-772
[2]   THE MG-QOL15 FOR FOLLOWING THE HEALTH-RELATED QUALITY OF LIFE OF PATIENTS WITH MYASTHENIA GRAVIS [J].
Burns, Ted M. ;
Grouse, C. K. ;
Wolfe, Gil I. ;
Conaway, Mark R. ;
Sanders, Donald B. .
MUSCLE & NERVE, 2011, 43 (01) :14-18
[3]   HISTORY OF OUTCOME MEASURES FOR MYASTHENIA GRAVIS [J].
Burns, Ted M. .
MUSCLE & NERVE, 2010, 42 (01) :5-13
[4]   The MG Composite A valid and reliable outcome measure for myasthenia gravis [J].
Burns, Ted M. ;
Conaway, Mark ;
Sanders, Donald B. .
NEUROLOGY, 2010, 74 (18) :1434-1440
[5]   Low-dose tacrolimus treatment in thymectomised and steroid dependent myasthenia gravis [J].
Kawaguchi, N ;
Yoshiyama, Y ;
Nemoto, Y ;
Munakata, S ;
Fukutake, T ;
Hattori, T .
CURRENT MEDICAL RESEARCH AND OPINION, 2004, 20 (08) :1269-1273
[6]   Clinical study of FK506 in patients with myasthenia gravis [J].
Konishi, T ;
Yoshiyama, Y ;
Takamori, M ;
Yagi, K ;
Mukai, E ;
Saida, T .
MUSCLE & NERVE, 2003, 28 (05) :570-574
[7]   MG-ADL: STILL A RELEVANT OUTCOME MEASURE [J].
Muppidi, Srikanth ;
Wolfe, Gil I. ;
Conaway, Mark ;
Burns, Ted M. .
MUSCLE & NERVE, 2011, 44 (05) :727-731
[8]   Long-term treatment of steroid-dependent myasthenia gravis patients with low-dose tacrolimus [J].
Nagaishi, Akiko ;
Yukitake, Motohiro ;
Kuroda, Yasuo .
INTERNAL MEDICINE, 2008, 47 (08) :731-736
[9]   Etanercept treatment in corticosteroid-dependent myasthenia gravis [J].
Rowin, J ;
Meriggioli, MN ;
Tüzün, E ;
Leurgans, S ;
Christadoss, P .
NEUROLOGY, 2004, 63 (12) :2390-2392
[10]   An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis [J].
Sanders, D. B. ;
Hart, I. K. ;
Mantegazza, R. ;
Shukla, S. S. ;
Siddiqi, Z. A. ;
De Baets, M. H. V. ;
Melms, A. ;
Nicolle, M. W. ;
Solomons, N. ;
Richman, D. P. .
NEUROLOGY, 2008, 71 (06) :400-406